Saw Palmetto denial
This article was originally published in The Tan Sheet
Executive Summary
High court refuses petitioners who requested the court review FDA's denial of a health claim linking saw palmetto to benign prostatic hyperplasia, law firm Emord & Associates says Oct. 12. Julian Whitaker, et al., filed the writ of certiorari earlier this year (1"The Tan Sheet" Jan. 19, 2004, p. 16)...
You may also be interested in...
Class Action Feeding Frenzy Could Chill On Legislation, Judicial Shift
Food and supplement class action complaints could be slowed by legislation in Congress and by judges potentially de-emphasizing reliance on FDA interpretation of statutes, say lawyers during FDLI conference discussion.
Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court
The Washington, D.C. federal appeals court upheld FDA's denial of a health claim petition linking saw palmetto extract to treatment of benign prostatic hypertrophy
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.